CVA Family Office’s Biogen BIIB Stock Holding History

CVA Family Office's BIIB Position: Q2 2026 in Review

CVA Family Office increased its Biogen (BIIB) stake by 1.9% in Q2 2026, buying an estimated $2.1K and bringing the position to 592 shares worth $128K. The position accounts for 0.01% of the portfolio, ranked #426.

CVA Family Office first reported a position in BIIB in Q1 2021 and has held it in 20 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

• CVA Family Office held 592 shares of Biogen worth $128K as of Q2 2026.
• CVA Family Office bought 11 Biogen shares in Q2 2026, an estimated $2.1K.
• Biogen made up 0.01% of CVA Family Office's portfolio in Q2 2026, its #426 holding.
• CVA Family Office first reported a position in Biogen in Q1 2021 and has held it in 20 quarters since.
• 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.